US equities |
SPCX $167.90 ▲+5.62% NVDA $237.40 ▲+1.47% MU $1,068.57 ▼-0.59% TSLA $377.16 ▲+1.77% MSFT $526.32 ▲+1.70% INTC $116.91 ▼-2.03% SNDK $1,725.81 ▲+0.34% META $745.30 ▲+2.37%
FinancialContent

Century Therapeutics, Inc. - Common Stock (NQ:IPSC)

1.471 -0.059 (-3.86%)
Delayed Quote Updated: 11:02 AM EDT, Oct 5, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Century Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Demystifying Century Therapeutics: Insights From 4 Analyst Reviews ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Century Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
4 Analysts Have This To Say About Century Therapeutics ↗
 
Via Benzinga
News headline image
5 Analysts Assess Century Therapeutics: What You Need To Know ↗
 
Via Benzinga
News headline image
Century Therapeutics: Q4 Earnings Insights ↗
 
Via Benzinga
News headline image
Century Therapeutics Announces Investigator-Initiated Phase 1/2 Trial of its iPSC-derived iNK Cell Therapy CNTY-101 in B-cell Mediated Autoimmune Diseases Sponsored by Internationally Renowned Key Opinion Leaders
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Stages Highest Single Day Move In 11 Months As Casdin Capital Bumps Its Stake To 5.4% ↗
 
Via Benzinga
News headline image
Century Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Upcoming Poster Presentations at the 2024 American Society of Hematology (ASH) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Guggenheim’s Inaugural Healthcare Innovation Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Century Therapeutics Strengthens Leadership Team with Appointments of Chief Financial Officer and Chief Scientific Officer
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Robinhood To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Thursday ↗
 
Via Benzinga
News headline image
IPSC Stock Earnings: Century Therapeutics Beats EPS for Q2 2024 ↗
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents Interim Results from Phase 1 ELiPSE-1 Study at ASCO 2024 Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents Preclinical Data Highlighting Advances in iPSC Platform Technology and Programs at 2024 ASGCT Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
IPSC Stock Earnings: Century Therapeutics Beats EPS, Misses Revenue for Q1 2024 ↗
IPSC stock results show that Century Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at Chardan’s 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing ↗
Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including systemic lupus erythematosus. $60 million private placement supports R&D... 
Via Benzinga
News headline image
Century Therapeutics Strengthens Position in Autoimmune Disease with Strategic Pipeline Expansion Supported by $60 Million Private Placement and Acquisition of Clade Therapeutics
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Presents New Preclinical Data Highlighting iPSC-derived Cell Therapy Platform Technology at the 2024 American Association for Cancer Research (AACR) Annual Meeting
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Tim Walbert and Paul Hoelscher to its Board of Directors
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Century Therapeutics to Present at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
IPSC Stock Earnings: Century Therapeutics Misses EPS, Misses Revenue for Q4 2023 ↗
IPSC stock results show that Century Therapeutics missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Century Therapeutics Reports Full Year 2023 Financial Results and Provides Business Updates
From Century Therapeutics, Inc.
Via GlobeNewswire
News headline image
Century Therapeutics Announces Six Upcoming Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Posters will highlight Century’s end-to-end cell therapy capabilities including expertise across iPSC reprogramming, gene editing, protein engineering, Allo-Evasion™ technology and computational... 
From Century Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >